Patients who suffer from epilepsy, which affects some 3.4 million people across the United States, report experiencing improved quality of life and a more restful night’s sleep after consuming the non-psychoactive cannabinoid CBD (cannabidiol). This is according to a recently published study featured in the peer-reviewed journal Epilepsy & Behavior. CBD, which constitutes a $2,770.8 million global market, appears to improve the tolerability of traditional epilepsy medications when consumed in conjunction with traditional over-the-counter (OTC) prescription drugs. What’s more, researchers say that “artisanal CBD” can ease a range of psychiatric symptoms, including anxiety. The study failed to highlight a noticeable difference in seizure control amongst cannabinoid consumers and non-consumers, study authors confirm that “both groups included a high number of individuals with no past month seizures.”

Posted By, Cannabis Central, 08/12/2021 08:00:00

Open article: